Compugen Ltd. (CGEN)

Market Cap	73.47M
Revenue (ttm)	7.50M
Net Income (ttm)	-33.69M
Shares Out	93.24M
EPS (ttm)	-0.39
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	237,280
Open	0.730
Previous Close	0.720
Day's Range	0.701 - 0.790
52-Week Range	0.510 - 3.570
Beta	2.70
Analysts	Buy
Price Target	5.76 (+630.96%)
Earnings Date	Feb 27, 2023

About CGEN

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I clinical study in patients with advanced malignancies as a monotherapy; Bapotulimab, a therapeutic antibody targeting ILDR2 that ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Aug 11, 2000
• Employees: 73
• Stock Exchange: NASDAQ
• Ticker Symbol: CGEN

Financial Performance

In 2022, Compugen's revenue was $7.50 million, an increase of 25.00% compared to the previous year's $6.00 million. Losses were -$33.69 million, -1.49% less than in 2021.

Analyst Forecast

According to 13 analysts, the average rating for CGEN stock is "Buy." The 12-month stock price forecast is $5.76, which is an increase of 630.96% from the latest price.

Price Target

$5.76

(630.96% upside)

Analyst Consensus: Buy